aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA total assets
Total assets on the balance sheet at the end of each period.
aTYR PHARMA's total assets was $69.83M at Jun 30, 2026. For fiscal 2025 it was $93.00M, down 4.0% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $129.68M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.00M | -4.0% |
| FY2024 | Dec 31, 2024 | $96.83M | -19.7% |
| FY2023 | Dec 31, 2023 | $120.65M | +26.0% |
| FY2022 | Dec 31, 2022 | $95.79M | -17.1% |
| FY2021 | Dec 31, 2021 | $115.54M | +198.3% |
| FY2020 | Dec 31, 2020 | $38.73M | +7.0% |
| FY2019 | Dec 31, 2019 | $36.19M | -31.4% |
| FY2018 | Dec 31, 2018 | $52.75M | -41.0% |
| FY2017 | Dec 31, 2017 | $89.36M | +11.0% |
| FY2016 | Dec 31, 2016 | $80.52M | -37.9% |
| FY2015 | Dec 31, 2015 | $129.68M | +528.1% |
| FY2014 | Dec 31, 2014 | $20.64M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $69.83M | -31.2% |
| Q1 FY2026 | Mar 31, 2026 | $79.65M | -18.1% |
| Q4 FY2025 | Dec 31, 2025 | $93.00M | -4.0% |
| Q3 FY2025 | Sep 30, 2025 | $106.65M | +16.4% |
| Q2 FY2025 | Jun 30, 2025 | $101.53M | -4.2% |
| Q1 FY2025 | Mar 31, 2025 | $97.25M | -14.1% |
| Q4 FY2024 | Dec 31, 2024 | $96.83M | -19.7% |
| Q3 FY2024 | Sep 30, 2024 | $91.62M | -26.7% |
| Q2 FY2024 | Jun 30, 2024 | $105.94M | -20.2% |
| Q1 FY2024 | Mar 31, 2024 | $113.25M | -17.2% |
| Q4 FY2023 | Dec 31, 2023 | $120.65M | +26.0% |
| Q3 FY2023 | Sep 30, 2023 | $125.07M | +30.2% |
| Q2 FY2023 | Jun 30, 2023 | $132.75M | +38.3% |
| Q1 FY2023 | Mar 31, 2023 | $136.84M | +30.6% |
| Q4 FY2022 | Dec 31, 2022 | $95.79M | -17.1% |
| Q3 FY2022 | Sep 30, 2022 | $96.06M | -22.5% |
| Q2 FY2022 | Jun 30, 2022 | $96.02M | +96.0% |
| Q1 FY2022 | Mar 31, 2022 | $104.78M | +90.1% |
| Q4 FY2021 | Dec 31, 2021 | $115.54M | +198.3% |
| Q3 FY2021 | Sep 30, 2021 | $123.92M | +197.6% |
| Q2 FY2021 | Jun 30, 2021 | $49.00M | +3.0% |
| Q1 FY2021 | Mar 31, 2021 | $55.13M | +1.3% |
| Q4 FY2020 | Dec 31, 2020 | $38.73M | +7.0% |
| Q3 FY2020 | Sep 30, 2020 | $41.64M | -4.8% |
| Q2 FY2020 | Jun 30, 2020 | $47.56M | -2.5% |
| Q1 FY2020 | Mar 31, 2020 | $54.45M | +9.1% |
| Q4 FY2019 | Dec 31, 2019 | $36.19M | -31.4% |
| Q3 FY2019 | Sep 30, 2019 | $43.75M | -26.8% |
| Q2 FY2019 | Jun 30, 2019 | $48.76M | -28.6% |
| Q1 FY2019 | Mar 31, 2019 | $49.92M | -36.4% |
| Q4 FY2018 | Dec 31, 2018 | $52.75M | -41.0% |
| Q3 FY2018 | Sep 30, 2018 | $59.77M | -36.7% |
| Q2 FY2018 | Jun 30, 2018 | $68.31M | +11.1% |
| Q1 FY2018 | Mar 31, 2018 | $78.47M | +19.4% |
| Q4 FY2017 | Dec 31, 2017 | $89.36M | +11.0% |
| Q3 FY2017 | Sep 30, 2017 | $94.49M | +10.0% |
| Q2 FY2017 | Jun 30, 2017 | $61.47M | – |
| Q1 FY2017 | Mar 31, 2017 | $65.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $80.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $85.93M | – |
See a number that looks wrong?